ALS Biopharma LLC is an emerging biotechnology company focused on the discovery of small-molecule therapeutics and diagnostics for the treatment of the debilitating neurological orphan indication of amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). The firm incorporates modern aspects of drug discovery including compound library synthesis and screening. In partnership with top academic and industrial laboratories, ALS Biopharma, LLC is researching both small molecule and biologic protein-based approaches to treat the disease.
